2024
Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Thakkar D, Hill B, Kositsky R, Tian S, Biral L, Russell V, Dave T, Love C, Roth C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, McCall C, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Gordillo C, Just B, Cohen J, Baim A, Barbello J, Cavallone E, Bachanova V, Laschen M, Teferra A, Lorcy F, Lamure S, Cartron G, Dardalhon V, Naresh K, Czader M, Reddy A, Thacker E, Parker C, Happ L, Dave S. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL. Blood 2024, 144: 3409. DOI: 10.1182/blood-2024-199758.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T-cell-related encephalopathy syndromeProgression-free survivalCAR-T therapyDiffuse large B-cell lymphoma patientsActivated B-cell typeInternational Prognostic IndexChimeric antigen receptorCAR-TCytokine release syndromeOverall survivalFavorable prognosisPrognostic scoreB cellsAssociated with worse progression-free survivalAssociated with progression-free survivalSubtype of diffuse large B-cell lymphomaHigher International Prognostic IndexInternational Prognostic Index scoreAchievement of complete remissionLarge B-cell lymphomaTumors prior to treatmentSide effectsMultiple extranodal sitesSurface markers CD19
2019
Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.Peer-Reviewed Original ResearchOverall response rateProgression-free survivalDiffuse large B-cell lymphomaLarge B-cell lymphomaCombination of nivolumabDose-escalation cohortsNon-GCB DLBCLPrimary refractory diseaseB-cell lymphomaOverall survivalDay 1Prior linesRefractory diseaseCell lymphomaNon-germinal center diffuse large B-cell lymphomaSingle-arm open-label studyResponse rateAutologous stem cell transplantCommon grade 3/4 toxicitiesMedian progression-free survivalNon-germinal centre DLBCLAnti-PD-1 antibodyDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsCAR T-cell therapy